Drugs / Ulocuplumab
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03225716 | Oct 2017 → Dec 2022 | Waldenstrom macroglobulinemia | Dana-Farber Cancer Institute | Terminated | No outcome recorded |
| Phase 1 | NCT01359657 | Sep 2011 → Mar 2016 | plasma cell myeloma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT01120457 | Aug 2010 → Nov 2014 | B-cell chronic lymphocytic leukemia, acute myeloid leukemia, diffuse large B-cell lymphoma, follicular lymphoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02305563 | Jan 2015 → Jun 2019 | leukemia | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT02666209 | — | plasma cell myeloma | Dana-Farber Cancer Institute | No longer available | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02472977 Comparator | Jul 2015 → Jan 2017 | cancer | Bristol-Myers Squibb | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ulocuplumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02472977 ↗ |
| Known as | BMS-936564 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02305563 ↗ |
| Known as | MDX-1338 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3039543 ↗ |
| Action | Inhibit | “Anti-CXCR4 (BMS-936564)” NCT01359657 ↗ |
| Modality | Monoclonal antibody | — CHEMBL3039543 ↗ |
| Modality | Protein / enzyme biologic | “Ulocuplumab is a type of protein called an antibody” NCT03225716 ↗ |
| Route | Intravenous | “Solution, Intravenously, 1-10 mg/kg” NCT01359657 ↗ |
| Target | CXCR4 | “Anti-CXCR4 (BMS-936564)” NCT01359657 ↗ |